Zepbound and Wegovy are both FDA-approved, once-weekly self-injected medications for chronic weight management in adults who meet BMI criteria. The core difference is the molecule: Wegovy contains semaglutide, which acts on the GLP-1 receptor, while Zepbound contains tirzepatide, which acts on two gut-hormone receptors, GIP and GLP-1. Both work, both are taken weekly, and neither is a shortcut around lifestyle — the better fit depends on your health history, side-effect tolerance, insurance, and a conversation with your prescriber.
What each drug actually is
Wegovy is the brand name for a higher-dose formulation of semaglutide approved specifically for weight management. (The same molecule at diabetes-focused dosing is sold as Ozempic.) It belongs to a class called GLP-1 receptor agonists, which mimic a natural gut hormone that rises after eating.
Zepbound is the brand name for tirzepatide approved for weight management. (The same molecule is sold as Mounjaro for type 2 diabetes.) Tirzepatide is often described as a "dual agonist" or "twincretin" because it engages both the GIP and GLP-1 receptors. For a deeper primer on this drug class, see our explainer on how GLP-1 medications work, and our overview of tirzepatide across Mounjaro and Zepbound.
How they work in the body
Both drugs slow how quickly the stomach empties, signal fullness to the brain, and reduce appetite and food "noise." The practical result for most people is smaller portions, fewer cravings, and eating less without constant willpower battles.
The mechanistic difference is the added GIP activity in tirzepatide. GIP is another incretin hormone involved in how the body handles food and insulin. Whether that second receptor fully explains tirzepatide's edge in trials is still being studied, but it is the leading theory for why average results tend to run higher.
Average weight loss in trials
In their respective large clinical trials, both medications produced substantial average weight loss well beyond what placebo plus lifestyle achieved. Semaglutide (Wegovy) was studied in the STEP trial program, which showed clinically meaningful reductions in body weight over more than a year at the top maintenance dose. Tirzepatide (Zepbound) was studied in the SURMOUNT program, which showed larger average reductions at its higher maintenance doses.
Two honest caveats matter here. First, these are averages — individual results vary widely, and some people respond strongly to one drug and modestly to the other. Second, the two drugs have not been compared head-to-head across every population, so cross-trial comparisons should be read as directional, not exact. The takeaway most clinicians accept: both are effective, and tirzepatide tends to produce somewhat greater average loss.
Side-by-side comparison
| Feature | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Drug class / mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Diabetes-branded twin | Mounjaro | Ozempic |
| How it's taken | Once-weekly injection under the skin | Once-weekly injection under the skin |
| Dose approach | Started low, stepped up gradually to a maintenance dose | Started low, stepped up gradually to a maintenance dose |
| Average weight loss | Higher on average in trials | Substantial in trials |
| Most common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting |
| Boxed warning | Thyroid C-cell tumor risk (see below) | Thyroid C-cell tumor risk (see below) |
Dosing and the injection schedule
Both are once-weekly injections you give yourself, typically in the abdomen, thigh, or upper arm, using a prefilled pen. Both follow a deliberate step-up schedule: you start at a low introductory dose and increase gradually over weeks or months. This slow titration is not a marketing quirk — it is the main strategy for reducing nausea and letting your gut adjust. Your clinician decides how fast to escalate and where to settle, and may pause or step back down if side effects are rough. Do not adjust doses on your own.
Side effects: mostly the same story
The side-effect profiles overlap heavily because both drugs act on GLP-1. The most common complaints are gastrointestinal: nausea, diarrhea, constipation, vomiting, and abdominal discomfort. These are usually most noticeable after a dose increase and often ease over time.
Less common but more serious risks reported for this drug class include pancreatitis, gallbladder problems, and — if you also take insulin or a sulfonylurea — low blood sugar. Rapid, severe, or persistent abdominal pain warrants prompt medical attention. For a fuller walk-through of what to expect and how to manage it, see our guide to semaglutide side effects, most of which apply to tirzepatide too.
Who should not take these drugs
These are prescription medications with real contraindications. Both carry a boxed warning about thyroid C-cell tumors seen in rodent studies. Because of that, neither drug should be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). They are also not for people with a known serious allergy to the medication.
Anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy, kidney problems, or who is pregnant, planning pregnancy, or breastfeeding should raise that with a clinician before starting. This is why the decision and the dosing are clinician-managed, not something to source or self-titrate independently.
Protecting muscle while you lose weight
Fast weight loss from any GLP-1 medication includes some loss of lean muscle, not just fat. That matters for midlife women especially, since muscle and bone are already under pressure from hormonal change. Two practical protections: eat enough protein spread across the day, and do regular resistance training to signal your body to keep muscle. These habits also help you sustain results if you and your clinician eventually taper the medication. This is general wellness guidance, not a substitute for a personalized plan.
Access, cost, and supply realities
On paper both are branded medications with high list prices, and out-of-pocket cost depends heavily on insurance coverage, which varies by plan and by whether you have a qualifying condition. Manufacturer savings programs and self-pay options exist for some patients and change over time. Supply of these medications has fluctuated, and availability of any given dose can vary. Compounded versions have circulated during shortages, but compounded drugs are not FDA-approved, are not the same as the branded product, and carry their own quality and safety uncertainties — a meaningful distinction worth discussing with a licensed prescriber and pharmacist rather than sourcing online.
So which one is "better"?
There is no universal winner. Tirzepatide (Zepbound) tends to produce greater average weight loss in trials, which makes it attractive to many. But Wegovy has a longer real-world track record, and semaglutide has additional cardiovascular-related data in its broader research program. Importantly, that reflects the wider body of semaglutide research rather than a head-to-head cardiovascular comparison of Zepbound versus Wegovy — the two have not been tested against each other on heart outcomes. Coverage or availability may also make one far more accessible than the other for you, and tolerability is individual too — some people simply feel better on one molecule.
The honest bottom line: both are legitimate, effective, FDA-approved tools for chronic weight management, and neither replaces nutrition, movement, and sleep. The right choice balances expected benefit, your medical history and contraindications, side-effect tolerance, cost, and supply — a decision best made with a clinician who knows your full picture. Talk to your doctor before starting, switching, or stopping either medication.
